anti ox 40 Search Results


anti ox40 mab  (Miltenyi Biotec)
95
Miltenyi Biotec anti ox40 mab
Anti Ox40 Mab, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti ox40 mab/product/Miltenyi Biotec
Average 95 stars, based on 1 article reviews
anti ox40 mab - by Bioz Stars, 2026-04
95/100 stars
  Buy from Supplier
reafinitytm  (Miltenyi Biotec)
95
Miltenyi Biotec reafinitytm

Reafinitytm, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/reafinitytm/product/Miltenyi Biotec
Average 95 stars, based on 1 article reviews
reafinitytm - by Bioz Stars, 2026-04
95/100 stars
  Buy from Supplier
rea621  (Miltenyi Biotec)
95
Miltenyi Biotec rea621
Used antibodies with respective conjugations (conj.) and dilutions for the flow-cytometric analyses.
Rea621, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rea621/product/Miltenyi Biotec
Average 95 stars, based on 1 article reviews
rea621 - by Bioz Stars, 2026-04
95/100 stars
  Buy from Supplier
anti cd134  (Miltenyi Biotec)
90
Miltenyi Biotec anti cd134
Used antibodies with respective conjugations (conj.) and dilutions for the flow-cytometric analyses.
Anti Cd134, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti cd134/product/Miltenyi Biotec
Average 90 stars, based on 1 article reviews
anti cd134 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
mb anti cd134 fitc ox40 350006 mouse  (Miltenyi Biotec)
91
Miltenyi Biotec mb anti cd134 fitc ox40 350006 mouse
Used antibodies with respective conjugations (conj.) and dilutions for the flow-cytometric analyses.
Mb Anti Cd134 Fitc Ox40 350006 Mouse, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mb anti cd134 fitc ox40 350006 mouse/product/Miltenyi Biotec
Average 91 stars, based on 1 article reviews
mb anti cd134 fitc ox40 350006 mouse - by Bioz Stars, 2026-04
91/100 stars
  Buy from Supplier
anti human cd134  (Miltenyi Biotec)
90
Miltenyi Biotec anti human cd134
Expression of co‐stimulatory and major histocompatibility complex (MHC) class II molecules in natural killer (NK) cells from healthy volunteers and systemic lupus erythematosus (SLE) patients. Peripheral blood mononuclear cells (PBMCs) from SLE patients (n = 29) and healthy controls (n = 29) were immunostained for CD3, CD56, CD80, CD86, <t>CD134</t> and human leucocyte antigen D‐related (HLA‐DR). Co‐stimulatory molecules and HLA‐DR were analysed from the CD3–CD56+ subset. Left and middle panel in (a–d). Dot‐plots from one healthy control and one SLE patient are shown. Numbers represent the percentage of CD80, CD86, CD134 or HLA‐DR‐positive cells from the CD3–CD56+ population. The cut‐offs for background fluorescence were based on isotype‐matched immunoglobulin (Ig)‐negative controls and fluorescence minus one (FMO) strategy. Right panel in (a–d). Analysis of the expression of CD80, CD86, CD134 or HLA‐DR in the CD3–CD56+ subset from SLE patients and healthy controls. Data are represented as the median and the interquartile range. *P < 0·05; **P < 0·005; ***P < 0·0001.
Anti Human Cd134, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti human cd134/product/Miltenyi Biotec
Average 90 stars, based on 1 article reviews
anti human cd134 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
cd134  (Miltenyi Biotec)
90
Miltenyi Biotec cd134
Expression of co‐stimulatory and major histocompatibility complex (MHC) class II molecules in natural killer (NK) cells from healthy volunteers and systemic lupus erythematosus (SLE) patients. Peripheral blood mononuclear cells (PBMCs) from SLE patients (n = 29) and healthy controls (n = 29) were immunostained for CD3, CD56, CD80, CD86, <t>CD134</t> and human leucocyte antigen D‐related (HLA‐DR). Co‐stimulatory molecules and HLA‐DR were analysed from the CD3–CD56+ subset. Left and middle panel in (a–d). Dot‐plots from one healthy control and one SLE patient are shown. Numbers represent the percentage of CD80, CD86, CD134 or HLA‐DR‐positive cells from the CD3–CD56+ population. The cut‐offs for background fluorescence were based on isotype‐matched immunoglobulin (Ig)‐negative controls and fluorescence minus one (FMO) strategy. Right panel in (a–d). Analysis of the expression of CD80, CD86, CD134 or HLA‐DR in the CD3–CD56+ subset from SLE patients and healthy controls. Data are represented as the median and the interquartile range. *P < 0·05; **P < 0·005; ***P < 0·0001.
Cd134, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd134/product/Miltenyi Biotec
Average 90 stars, based on 1 article reviews
cd134 - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
ox40  (Miltenyi Biotec)
95
Miltenyi Biotec ox40
Expression of co‐stimulatory and major histocompatibility complex (MHC) class II molecules in natural killer (NK) cells from healthy volunteers and systemic lupus erythematosus (SLE) patients. Peripheral blood mononuclear cells (PBMCs) from SLE patients (n = 29) and healthy controls (n = 29) were immunostained for CD3, CD56, CD80, CD86, <t>CD134</t> and human leucocyte antigen D‐related (HLA‐DR). Co‐stimulatory molecules and HLA‐DR were analysed from the CD3–CD56+ subset. Left and middle panel in (a–d). Dot‐plots from one healthy control and one SLE patient are shown. Numbers represent the percentage of CD80, CD86, CD134 or HLA‐DR‐positive cells from the CD3–CD56+ population. The cut‐offs for background fluorescence were based on isotype‐matched immunoglobulin (Ig)‐negative controls and fluorescence minus one (FMO) strategy. Right panel in (a–d). Analysis of the expression of CD80, CD86, CD134 or HLA‐DR in the CD3–CD56+ subset from SLE patients and healthy controls. Data are represented as the median and the interquartile range. *P < 0·05; **P < 0·005; ***P < 0·0001.
Ox40, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ox40/product/Miltenyi Biotec
Average 95 stars, based on 1 article reviews
ox40 - by Bioz Stars, 2026-04
95/100 stars
  Buy from Supplier
anti ox40 apc mab  (Miltenyi Biotec)
90
Miltenyi Biotec anti ox40 apc mab
Expression of co‐stimulatory and major histocompatibility complex (MHC) class II molecules in natural killer (NK) cells from healthy volunteers and systemic lupus erythematosus (SLE) patients. Peripheral blood mononuclear cells (PBMCs) from SLE patients (n = 29) and healthy controls (n = 29) were immunostained for CD3, CD56, CD80, CD86, <t>CD134</t> and human leucocyte antigen D‐related (HLA‐DR). Co‐stimulatory molecules and HLA‐DR were analysed from the CD3–CD56+ subset. Left and middle panel in (a–d). Dot‐plots from one healthy control and one SLE patient are shown. Numbers represent the percentage of CD80, CD86, CD134 or HLA‐DR‐positive cells from the CD3–CD56+ population. The cut‐offs for background fluorescence were based on isotype‐matched immunoglobulin (Ig)‐negative controls and fluorescence minus one (FMO) strategy. Right panel in (a–d). Analysis of the expression of CD80, CD86, CD134 or HLA‐DR in the CD3–CD56+ subset from SLE patients and healthy controls. Data are represented as the median and the interquartile range. *P < 0·05; **P < 0·005; ***P < 0·0001.
Anti Ox40 Apc Mab, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti ox40 apc mab/product/Miltenyi Biotec
Average 90 stars, based on 1 article reviews
anti ox40 apc mab - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier
pe anti rat cd134 ox 40  (BioLegend)
N/A
PE anti rat CD134 OX 40 OX 40 Isotype Mouse IgG2b κ Reactivity Rat Apps FC Size 100 μg
   Buy from Supplier
apc anti mouse cd134 ox 40  (BioLegend)
N/A
APC anti mouse CD134 OX 40 OX 86 Isotype Rat IgG1 κ Reactivity Mouse Apps FC Size 25 μg
   Buy from Supplier
purified anti rat cd252 ox 40 ligand  (BioLegend)
N/A
Purified anti rat CD252 OX 40 Ligand ATM 2 Isotype Mouse IgG1 κ Reactivity Rat Apps FC Size 50 μg
   Buy from Supplier

Image Search Results


Journal: STAR Protocols

Article Title: A protocol for high-throughput screening for immunomodulatory compounds using human primary cells

doi: 10.1016/j.xpro.2023.102405

Figure Lengend Snippet:

Article Snippet: CD134 (OX40) Antibody, anti-human, APC, REAfinityTM (Clone- REA621) , Miltenyi Biotec , Order Number: 130-122-227.

Techniques: Recombinant, Sterility, Modification, Staining, Saline, Multiplex Assay, Software

Used antibodies with respective conjugations (conj.) and dilutions for the flow-cytometric analyses.

Journal: Frontiers in Immunology

Article Title: Polyfunctional T cells and unique cytokine clusters imprint the anti rAAV2/rAAV9 vector immune response

doi: 10.3389/fimmu.2024.1450524

Figure Lengend Snippet: Used antibodies with respective conjugations (conj.) and dilutions for the flow-cytometric analyses.

Article Snippet: CD134 , PE-Vio770 , 1:50 , REA621 , 130-120-723 , Miltenyi.

Techniques:

Expression of co‐stimulatory and major histocompatibility complex (MHC) class II molecules in natural killer (NK) cells from healthy volunteers and systemic lupus erythematosus (SLE) patients. Peripheral blood mononuclear cells (PBMCs) from SLE patients (n = 29) and healthy controls (n = 29) were immunostained for CD3, CD56, CD80, CD86, CD134 and human leucocyte antigen D‐related (HLA‐DR). Co‐stimulatory molecules and HLA‐DR were analysed from the CD3–CD56+ subset. Left and middle panel in (a–d). Dot‐plots from one healthy control and one SLE patient are shown. Numbers represent the percentage of CD80, CD86, CD134 or HLA‐DR‐positive cells from the CD3–CD56+ population. The cut‐offs for background fluorescence were based on isotype‐matched immunoglobulin (Ig)‐negative controls and fluorescence minus one (FMO) strategy. Right panel in (a–d). Analysis of the expression of CD80, CD86, CD134 or HLA‐DR in the CD3–CD56+ subset from SLE patients and healthy controls. Data are represented as the median and the interquartile range. *P < 0·05; **P < 0·005; ***P < 0·0001.

Journal: Clinical and Experimental Immunology

Article Title: Analysis of the regulatory function of natural killer cells from patients with systemic lupus erythematosus

doi: 10.1111/cei.13073

Figure Lengend Snippet: Expression of co‐stimulatory and major histocompatibility complex (MHC) class II molecules in natural killer (NK) cells from healthy volunteers and systemic lupus erythematosus (SLE) patients. Peripheral blood mononuclear cells (PBMCs) from SLE patients (n = 29) and healthy controls (n = 29) were immunostained for CD3, CD56, CD80, CD86, CD134 and human leucocyte antigen D‐related (HLA‐DR). Co‐stimulatory molecules and HLA‐DR were analysed from the CD3–CD56+ subset. Left and middle panel in (a–d). Dot‐plots from one healthy control and one SLE patient are shown. Numbers represent the percentage of CD80, CD86, CD134 or HLA‐DR‐positive cells from the CD3–CD56+ population. The cut‐offs for background fluorescence were based on isotype‐matched immunoglobulin (Ig)‐negative controls and fluorescence minus one (FMO) strategy. Right panel in (a–d). Analysis of the expression of CD80, CD86, CD134 or HLA‐DR in the CD3–CD56+ subset from SLE patients and healthy controls. Data are represented as the median and the interquartile range. *P < 0·05; **P < 0·005; ***P < 0·0001.

Article Snippet: Characteristics clinic and demographics of systemic lupus erythematosus (SLE) patients table ft1 table-wrap mode="anchored" t5 Table 2 caption a7 Drug combination Number of patients Methotrexate + anti‐malarial 3 Methotrexate + prednisone + cyclosporin Methotrexate + prednisone 11 Prednisone + azathioprine Methotrexate + prednisone + azulfidine Methotrexate + prednisone + anti‐malarial 6 Methotrexate + prednisone + anti‐malarial + cyclophosphamide Prednisone + anti‐malarial Anti‐malarial 5 Prednisone + anti‐malarial + azathioprine Anti‐malarial + mycophenolate mofetil Prednisone + anti‐malarial + cyclophosphamide + mycophenolate mofetil Methotrexate + prednisone + azathioprine Mycophenolate mofetil methotrexate + prednisone + anti‐malarial + mycophenolate mofetil Prednisone Mycophenolate mofetil + tacrolimus Methotrexate 4 Open in a separate window Combination therapy schemes used in systemic lupus erythematosus (SLE) patients Antibodies The following monoclonal anti‐human antibodies were used: anti‐human CD3 labelled with peridinin chlorophyll (PerCP), anti‐human NKp46‐phycoerythrin (PE), anti‐human NKG2D‐PE, anti‐human CD107a [lysosomal‐associated membrane protein 1 (LAMP‐1)] coupled to PE/cyanin 7 (Cy7), anti‐human CD11c‐PerCP/Cy5 and anti‐human human leucocyte antigen D‐related (HLA‐DR) coupled to allophycocyanin (APC)/Cy7 (BioLegend, San Diego, CA), anti‐human CD56 labelled with APC, anti‐human ILT2‐PE, anti‐human CD80‐fluorescein isothiocyanate (FITC), anti‐human CD86 coupled to PE and anti‐human CD134 (OX40)‐PE, anti‐HLA‐DR‐PE (eBioscience, San Diego, CA, USA), anti‐human CD161‐PE (BD Biosciences, San José, CA, USA), anti‐human CD159a/NKG2A labelled with phycoerythrin [magnetic affinity cell sorting (MACS); Miltenyi Biotec, Bergisch Gladbach, Germany] and anti‐human NKG2C PE‐conjugated anti‐human NKp30‐PE (R&D Systems, Minneapolis, MN, USA).

Techniques: Expressing, Immunopeptidomics, Control, Fluorescence